Toxicity profiles of immunotherapy
- PMID: 28716652
- DOI: 10.1016/j.pharmthera.2017.07.005
Toxicity profiles of immunotherapy
Abstract
Immunotherapies are changing the landscape of advanced solid tumor treatment. These therapies have different mechanisms of action and include oncolytic viruses, checkpoint inhibitors, such as CTLA-4 or PD1/PD-L1 monoclonal antibodies, and CSF-1R antibodies. Given the growing therapeutic impact of these agents in oncology, it is important to better understand their properties. Immunotherapies generate new toxicity profiles that are called immune-related adverse events and require specific management. This review focuses on the mechanisms of action of such side effects, as well as their description and their general management.
Keywords: Checkpoint inhibitors; Management; Mechanisms; Oncolytic viruses; irAEs.
Copyright © 2017 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous